Jazz
Jazz Releases Full Survival Data for Zepzelca in Lung Cancer at ASCO 2025
Jazz Pharmaceuticals; Zepzelca; lurbinectedin; lung cancer; small cell lung cancer; Tecentriq; atezolizumab; IMforte trial; overall survival; progression-free survival; ASCO 2025
Jazz Pharmaceuticals to Acquire Chimerix for $935 Million, Gaining Promising Brain Tumor Drug Dordaviprone
Jazz Pharmaceuticals, Chimerix, Acquisition, Dordaviprone, Brain tumor, H3 K27M-mutant diffuse glioma, FDA approval, Oncology pipeline
Jazz Pharmaceuticals Announces CEO Succession Plan as Co-Founder Bruce Cozadd Prepares to Retire
Jazz Pharmaceuticals, Bruce Cozadd, CEO succession plan, retirement, biopharmaceutical company, leadership transition
Jazz Pharmaceuticals Advances Combination Therapy for Extensive-Stage Small Cell Lung Cancer
Jazz Pharmaceuticals, Zepzelca, lurbinectedin, atezolizumab, ES-SCLC, first-line maintenance therapy, small cell lung cancer, Phase 3 IMforte trial
Jazz Pharmaceuticals’ Epidiolex Fails to Meet Primary Endpoint in Japanese Phase 3 Trial for Treatment-Resistant Epilepsies
Jazz Pharmaceuticals, Epidiolex, Cannabidiol Oral Solution, Treatment-Resistant Epilepsies, Phase 3 Trial, Japan
Jazz Pharmaceuticals’ Essential Tremor Drug Candidate Fails to Meet Primary Endpoint in Phase IIb Trial
Jazz Pharmaceuticals, suvecaltamide, essential tremor, phase IIb trial, primary endpoint, calcium channel modulator
Jazz Pharmaceuticals Presents Groundbreaking HER2 Biliary Tract Cancer Data Ahead of FDA Decision
Jazz Pharmaceuticals, HER2, Biliary Tract Cancer, FDA Decision, Zanidatamab, Priority Review
Jazz Pharmaceuticals Expands Oncology Pipeline with Redx’s KRAS Inhibitor Program
Kirsten murine sarcoma virus, Jazz, Redx, Inhibitor